Rofleponide 21-palmitate

Rofleponide 21-palmitate 是一种亲脂性皮质类固醇前药,可减轻皮下水肿、降低血浆触珠蛋白水平及血浆 IL-6、KC、IP-10、MCP-1 水平,并能增强并延长脂质纳米颗粒制剂中 mRNA 编码蛋白的表达。
产品编号: MS-A44327 CAS No.: 144653-57-6 分子式: C41H64F2O7 分子量: 706.94
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Rofleponide 21-palmitate 是一种亲脂性皮质类固醇前药,可减轻皮下水肿、降低血浆触珠蛋白水平及血浆 IL-6、KC、IP-10、MCP-1 水平,并能增强并延长脂质纳米颗粒制剂中 mRNA 编码蛋白的表达。

生物实验数据

生物活性 Rofleponide 21-palmitate is a lipophilic corticosteroid prodrug that reduces subcutaneous edema, decreases plasma haptoglobin levels and plasma levels of IL-6, KC, IP-10, and MCP-1, and enhances and prolongs the expression of mRNA-encoded proteins in lipid nanoparticle formulations.
体内研究
(In Vivo)

Rofleponide 21-palmitate (Rofleponide 21-palmitate 与 mRNA 的质量比为 1:1-1:30;固定 mRNA 剂量 0.3 mg/kg;皮下注射;单次给药) 在基于 DLin-MC3-DMA 的 LNP 中,可显著降低雌性 Crl:Cd1 (ICR) 小鼠体内 LNP 诱导的水肿及血浆触珠蛋白水平,同时增强并延长 mRNA 1 的蛋白表达。
Rofleponide 21-palmitate (Rofleponide 21-palmitate:mRNA 重量比 1:1;固定 mRNA 剂量 0.3 mg/kg;皮下注射;单次给药) 在基于 DLin-MC3-DMA 的 LNP 中,可消除小鼠体内 LNP 诱导的水肿、降低血浆触珠蛋白水平、延长 mRNA 1 蛋白表达。
Rofleponide 21-palmitate (Rofleponide 21-palmitate:mRNA 重量比 1:1;固定 mRNA 剂量 0.3 mg/kg;皮下注射;单次给药) 在基于 Merck-32 的 LNP 中可显著降低雌性小鼠体内由 LNP 诱导的水肿及血浆触珠蛋白水平,同时提升 mRNA 1 蛋白的表达水平。

Animal Model: Crl:Cd1(ICR) mice (female, ~12 weeks old)
Dosage: Rofleponide 21-palmitate:mRNA weight ratios of 1:1, 1:10, 1:30; fixed mRNA dose of 0.3 mg/kg
Administration: s.c.; single dose
Result: Significantly reduced edema scoring across all rofleponide 21-palmitate LNP groups compared to non-anti-inflammatory LNPs at 24 hours post-administration.
Significantly reduced plasma haptoglobin levels across all ratios compared to non-anti-inflammatory LNPs at 24 hours post-administration.
Increased and prolonged mRNA 1 protein expression over 0-24 hours compared to non-anti-inflammatory LNPs.
Animal Model: Crl:Cd1(ICR) mice (female, ~12 weeks old)
Dosage: Rofleponide 21-palmitate:mRNA weight ratio of 1:1; fixed mRNA dose of 0.3 mg/kg
Administration: s.c.; single dose
Result: Achieved edema scoring of 0 at 24, 48, and 72 hours post-administration, compared to a score of 5 for rofleponide-containing LNPs at the same molar dose.
Significantly lowered plasma haptoglobin levels at 25, 50, and 75 hours post-administration compared to rofleponide-containing LNPs.
Increased and prolonged mRNA 1 protein expression.
Reached a rofleponide plasma concentration peak of ~6 nM at 2.5 hours post-administration, with a gradual decline over 24 hours, while Rofleponide-containing LNPs showed an initial peak of ~75 nM followed by a rapid drop to near 0 by 5 hours.\n
Reduced edema scoring at 24 hours post-administration compared to non-anti-inflammatory Merck-32 LNPs.
Significantly reduced plasma haptoglobin levels at 24 hours post-administration compared to non-anti-inflammatory Merck-32 LNPs.
Increased mRNA 1 protein expression over 0-24 hours.
Animal Model: Crl:Cd1(ICR) mice (female, ~12 weeks old)
Dosage: Rofleponide 21-palmitate:mRNA weight ratio of ~1:1; fixed mRNA dose of 0.3 mg/kg
Administration: s.c.; single dose
Result: Reduced edema scoring to near 0 at 24 hours post-administration.
Significantly reduced plasma haptoglobin levels at 24 hours post-administration compared to non-anti-inflammatory LNPs.
Increased and prolonged mRNA 1 protein expression over 0-24 hours, reaching ~0.8 ng/mL at 24 hours compared to near 0 ng/mL for non-anti-inflammatory LNPs.

化学信息

分子量 706.94
分子式 C41H64F2O7
CAS No. 144653-57-6

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础